Biotech beat

Funding

The Funding beat on Biotech tracks 59 verified stories, with 3 clearing multi-source corroboration in the last 7 days at mean impact 5/10 — live SQLite counts, not editorial weighting.

9 stories

Beat pulse

Last 7 days · Funding

3 stories
5 avg impact
0% positive
0% negative
vs prior 7 days -2 -2 stories vs prior 7 days

Impact 5.0/10 (-0.4 vs prior). Counts are stories in our record, not a market forecast.

Open the change report
  • 100% neutral

Stories appear on this page because our classification stage assigned them this category as their primary topic — each story receives exactly one category per niche, chosen from a fixed list, so a story that touches both a funding round and a product launch in the same week sorts into whichever category best matches its dominant subject, not both. This keeps each category page focused on one beat rather than a blend of unrelated developments, and applies the same source-verification standard used across every story on this site. Sentiment measures the directional read of each development for this category specifically, not the tone of the reporting, and impact weights how consequential a development is — regulatory, financial, or operational — rather than how widely it was syndicated across outlets.

Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.

Beat actors

Who drives Funding

Entities appearing in at least two verified funding stories on this desk — ranked by mention count, not editorial preference.

Neutral 5

Oncare Secures ₹27 Cr Series A to Scale Oncology Care Across India

Oncology startup Oncare has raised ₹27 Crore ($3.2 million) in a Series A funding round led by Sky Impact Capital. The capital will drive the expansion of its specialized clinic network from Delhi NCR into Tier-2 and Tier-3 Indian markets to bridge the gap in cancer care accessibility.

Verified by 2 sources
Neutral 5

Rakovina Therapeutics Upsizes Financing to $2M to Fuel Oncology Pipeline

Rakovina Therapeutics has announced an upsized financing package totaling up to $2.0 million, split between convertible debentures and a private placement. The capital injection is earmarked for near-term operations as the company advances its DNA-damage response (DDR) oncology programs.

Verified by 2 sources
Neutral 5

Psyence BioMed Secures Supply Chain via Strategic PsyLabs Equity Investment

Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.

Verified by 2 sources
Positive 6

Wellgistics Health Enters $6.3B Mental Health AI Market via Stealth Investment

Wellgistics Health has executed a strategic investment in a stealth-mode mental health AI startup, signaling a major pivot toward high-margin digital health software. The move positions the company to capture a significant share of the $6.3 billion mental health software market through advanced artificial intelligence capabilities.

Verified by 2 sources

Source: Seeking Alpha · newjerseytelegraph.com

About Biotech Funding coverage

According to our own tracking database, this category has accumulated 59 funding stories since coverage began. This page aggregates the latest funding stories within our biotech coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track biotech venture funding, grants and surface the angles a domain expert would actually read.

Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the biotech beat.

Stories only surface on this page once the classifier scores them at a minimum 35 percent relevance to the category. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong on this page — a wrong stat, a broken source link, a miscategorized story? Report a data issue.

SignalWhat it tells you
Verified by N sourcesConfidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated.
Impact score (1-10)Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on.
SentimentFive-tier classification (very bullish through very bearish) trained on labeled biotech-specific corpora.
Time stampRecency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed.